Repair of a Damaged Cornea Using Cells Derived from Induced Pluripotent Stem Cells

Since the discovery of induced pluripotency more than a decade ago, researchers have been working towards the use of this technology to produce cells for use in tissue engineering and regenerative therapies. Induced pluripotent stem cells are functionally equivalent to embryonic stem cells; given suitable recipes and methods for the surrounding environment and signals, they can be made to generate any of the cell types in the body. The cornea of the eye is a comparatively simple starting point for tissue engineering, easier to work with in many ways, in generating tissues and in delivering cells to the patient. Here, the first repair of a human cornea is reported, using tissue structures produced from induced pluripotent stem cells.

A Japanese woman in her forties has become the first person in the world to have her cornea repaired using reprogrammed stem cells. The woman has a disease in which the stem cells that repair the cornea, a transparent layer that covers and protects the eye, are lost. The condition makes vision blurry and can lead to blindness. To treat the woman, researchers created sheets of corneal cells from induced pluripotent stem (iPS) cells. These are made by reprogramming adult skin cells from a donor into an embryonic-like state from which they can transform into other cell types, such as corneal cells.

The woman's cornea remained clear and her vision had improved since the transplant a month ago. Currently people with damaged or diseased corneas are generally treated using tissue from donors who have died, but there is a long waiting list for such tissue in Japan. Japan has been ahead of the curve in approving the clinical use of iPS cells, which were discovered by stem-cell biologist Shinya Yamanaka. Japanese physicians have also used iPS cells to treat spinal cord injury, Parkinson's disease, and another eye disease. The Japanese health ministry gave permission to try the procedure on four people. The team is planning the next operation for later this year and hope to have the procedure in the clinic in five years.



The eye field is becoming an active area for stem cells - and gene therapy.
Reneuron are doing a stem cell trial for retinal rather than corneal degeneration:

"Open label prospective study of the safety and tolerability of the human retinal progenitor cell (hRPC) therapy candidate in the treatment of patients with retinitis pigmentosa" - reports are that it is very effective - ie can improve eyesight by 4 lines from registered blind( 20/200 on the US ETDRS scale ) to 20/60 ie eligible to drive with yearly eye test.
Not bad!

Posted by: JLH at September 12th, 2019 6:45 AM

Waste of time for iPs - too many competitors already on the market that work very well

Best to focus on the retina - much bigger unmet market

What ever happened to the Lanza / Ocata / Astellas trial??

Posted by: Quinn Binnembaum at September 12th, 2019 7:15 AM

@Quinn Binnembaum
Can you recommend something worth looking into for investing in the longevity space and available for retail investor(stocks)?

Posted by: Andriy at September 12th, 2019 1:26 PM
Comment Submission

Post a comment; thoughtful, considered opinions are valued. New comments can be edited for a few minutes following submission. Comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.

Note that there is a comment feed for those who like to keep up with conversations.